Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review
Key claim: EHA 2025 highlighted advances in MPN therapy including elritercept for myelofibrosis, pelabresib plus ruxolitinib in the phase III MANIFEST-2 trial, and INCA035784, a novel T cell-redirecting antibody targeting CALR mutations.
Abstract
The 30th European Hematology Association (EHA) Congress marked a pivotal year in advancing MPN treatment and understanding. Breakthroughs in novel therapies, disease biology, and molecular risk stratification highlighted EHA 2025 Congress. Major presentations included elritercept for myelofibrosis showing haematological and clinical benefits with reductions in splenomegaly; pelabresib plus ruxolitinib in the phase III MANIFEST-2 study; and INCA035784, a novel T cell-redirecting antibody for patients with different types of calreticulin mutations.
Why this matters
For the symptom-management area, this EHA 2025 synthesis matters because the agents highlighted (elritercept, pelabresib + ruxolitinib, INCA035784) all have downstream effects on splenomegaly-related symptom burden, even when their primary endpoints target anemia or disease modification. It reinforces that emerging MPN therapeutics increasingly bundle spleen-volume reduction with broader symptom relief, expanding the pharmacologic options catalogued under splenomegaly.